In today’s briefing:
- Jiangsu Hengrui Pharma A/H Listing – Recent Updates and Thoughts on A/H Premium
- Amvis Holdings Inc (7071 JP): Deteriorating Margin to Limit Near-Term Upside Potential
- BrainStorm Cell Therapeutics (BCLI) – Fundamentals Update 09042025
- Is McKesson Wall Street’s Safe Haven? How This Drug Giant Can Thrive In Uncertain Times!
Jiangsu Hengrui Pharma A/H Listing – Recent Updates and Thoughts on A/H Premium
- Jiangsu Hengrui Medicine (600276 CH) (JHP), a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.
- JHP has been ranked as one of the global Top 50 pharmaceutical companies by Pharm Exec for six consecutive years since 2019.
- We have looked at the company’s past performance in our previous note. In this note, we talk about the recent updates and provide our thoughts on the possible A/H premium.
Amvis Holdings Inc (7071 JP): Deteriorating Margin to Limit Near-Term Upside Potential
- While Amvis Holdings Inc (7071 JP) expects decelerating revenue growth of 26% for FY25 (FY24: 33%), EBITDA, operating, and net profits are likely to decline 9–22%.
- Personnel expenses as % of sales surged to 49.3% in Q1FY25 from 44.6% in Q1FY24. The trend is expected to continue with the increase in staff and training cost.
- Decelerating revenue growth, margin erosion, aggressive business expansion, and overhang related to improperly claimed medical service fee will limit the near-term upside potential for Amvis.
BrainStorm Cell Therapeutics (BCLI) – Fundamentals Update 09042025
- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s).
- Recent micro capitalization and patent development buy time for non-dilutive funding to be secured.
- BCLI’s Nasdaq compliance for minimum price was regained in late Oct 24, which helps maintain capital access.
Is McKesson Wall Street’s Safe Haven? How This Drug Giant Can Thrive In Uncertain Times!
- As markets reel from the reimposition of tariffs on Mexico and Canada, investors are scrambling for stability in a landscape marked by global trade uncertainty and rising macroeconomic risk.
- While the broader market has faltered, McKesson Corporation, the largest drug distributor in the U.S., has quietly emerged as a defensive standout.
- The company’s supply chain resilience, diversified business model, and essential role in healthcare delivery position it as a stock that is potentially insulated from the brunt of economic and policy headwinds.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
